Flash FinanceUS
Market open S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Black Diamond Therapeutics, Inc. (BDTX)

Black Diamond Therapeutics updates silevertinib data; FDA supports Phase 3 plan

Negative Impact 4 of 5 other

Black Diamond Therapeutics reported updated Phase 2 data for silevertinib in frontline EGFR non-classical mutation lung cancer and said feedback from an October 1, 2026 FDA End of Phase 2 meeting supports a pivotal program. Its third-quarter financial results show a wider net loss than a year earlier, and cash, cash equivalents and investments declined to $102.0 million, which the company says funds operations into the second half of 2028.

Key points

  • Q3 2026 net loss was $10.0 million, compared with $8.5 million in Q3 2025; neither quarter had license revenue.
  • Nine-month 2026 net loss was $28.95 million, versus net income of $37.5 million in the first nine months of 2025, which included $70 million of license revenue.
  • Cash, cash equivalents and investments were $102.0 million at September 30, 2026, down from $128.7 million at December 31, 2025.
  • The planned global Phase 3 trial would enroll 300 patients and could start in the second quarter of 2027, with preliminary data anticipated in 2028.

The filing

CompanyBlack Diamond Therapeutics, Inc. (BDTX)
Form8-K, current report
Filed with the SECNov 10, 2026, 6:28 AM ET
Accession number0001701541-26-000030

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 6:36 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.